Prostate Cancer | Unmet Need | Metastatic Hormone Sensitive | US/EU5 | 2020
The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved in recent years with the approval of hormonal agents such as Zytiga (Johnson & Johnson), Xtandi (Pfizer / Astellas Pharma), and the next-generation androgen receptor inhibitor Erleada (Johnson & Johnson). Although these therapies have improved patient outcomes, substantial unmet need remains for novel therapies with better efficacy and improved safety and tolerability. Therefore, the therapeutic management of newly diagnosed mHSPC presents an enormous commercial opportunity for drug developers.
QUESTIONS ANSWERED
- What treatment drivers and goals are most likely to influence the choice of therapy for newly diagnosed mHSPC?
- What attributes are key influencers of prescribing, and what are the hidden opportunities for drug developers?
- What are the prevailing areas of unmet need and opportunity in this patient population?
- What trade-offs across different clinical attributes and prices are acceptable to U.S. and European medical oncologists for a hypothetical therapy for newly diagnosed mHSPC?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. medical oncologists and 30 European medical oncologists
Key drugs: Zytiga, Erleada, Xtandi, Taxotere / docetaxel generics
